Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 1998

View Archived Issues

New oral ultrasound contrast agent approved by FDA

BioStratum's novel viral vaccine protects against AIDS in animal model; company forms subsidiary

Stromelysin inhibitor Bay-12-9566 enters clinical testing for a second indication

Amgen evaluates novel TNF-targeted immunotherapy in patients with active RA

Oral bisphosphonate effectively treats, prevents corticosteroid-induced bone loss and fractures

SU-101 may be indicated for combination therapy of prostate cancer

Double protease inhibitor therapy incorporating amprenavir effective in HIV-positive patients

IntraBiotics initiates phase II clinical trial for oral mucositis treatment

DuPont Pharma selects second-generation NNRTIs for clinical development

Asta Medica focuses efforts on development of GnRH antagonist for enhancing fertility

New cephems from Takeda for bacterial infections

Potent and selective nicotinic acetylcholine receptor ligands prepared at Synthelabo

Ultra-short-acting neuromuscular blockers with advantages over available agents

Series of nNOS inhibitors patented by Mitsui

Teijin's new vitamin D derivatives induce cell differentiation

HMR describes preliminary biological activity of new heptaene antifungals

Multiple preclinical and phase I study results presented for AIT-082 at neuroscience meeting

NIH sponsors clinical study of novel antiprogestin CDB-2914

GPI-6150: data provide further support for development as a treatment for stroke

Excellent results obtained during IVF procedures incorporating ganirelix acetate

Neuroprotective effects of HU-211 in soman-treated rats

PARAGON A establishes effective dose of lamifiban in unstable angina

New dopamine D4 antagonist from Warner-Lambert characterized in preclinical studies

Nolvadex now available for breast cancer prevention

Putative cognition enhancer CR-2249 also exerts anxiolytic, antidepressant effects

NO scavengers may be indicated in the treatment of diabetes-induced endothelial dysfunction

Gilead's adefovir dipivoxil extensively covered at AASLD meeting

Collateral Therapeutics draws nearer to an effective gene therapy for CHF

ML Laboratories granted second license from U.K. authorities for its dry powder inhaler